Author: digi

Pharmacovigilance Oversight Failures in Clinical Trial Audit Reports

August 11, 2025

Pharmacovigilance Oversight Failures in Clinical Trial Audit Reports Understanding Pharmacovigilance Oversight Failures in Clinical Trial Audits Why Pharmacovigilance Oversight Matters in Clinical Trials Pharmacovigilance (PV) is the cornerstone of patient safety in clinical research. It encompasses the detection, assessment, and prevention of adverse effects or any other drug-related issues during the development of investigational products….

Regulatory Audit Findings, Safety Reporting Audit Findings

SOP for Vulnerable Populations and Witness Consent

August 11, 2025

digi

SOP for Vulnerable Populations and Witness Consent { “@context”: “https://schema.org”, “@type”: “Article”, “mainEntityOfPage”: { “@type”: “WebPage”, “@id”: “https://www.Clinicalstudies.in/SOP-for-Vulnerable-Populations-and-Witness-Consent” }, “headline”: “SOP for Vulnerable Populations and Witness Consent in Clinical Trials”, “description”: “This SOP provides a detailed regulatory framework for obtaining consent from vulnerable populations, including the use of impartial witnesses, in compliance with ICH GCP,…

Global SOPs (Applicable to all Agencies), SOP for GCP

Using eLearning Tools for Pre-Meeting Training

August 10, 2025

digi

Using eLearning Tools for Pre-Meeting Training Using eLearning Tools to Enhance Pre-Meeting Investigator Training Introduction: The Shift to Digital Training in Clinical Research As clinical trials become more global and complex, the need for scalable, efficient, and compliant investigator training has intensified. Traditional face-to-face investigator meetings are resource-intensive and often limited by travel, time zones,…

Investigator and Site Training, Investigator Meetings

Age Stratification in Randomization and Analysis

August 10, 2025

digi

Age Stratification in Randomization and Analysis How to Implement Age Stratification in Randomization and Statistical Analysis Why Age Stratification Matters in Protocol Design Age is one of the strongest effect modifiers in medicine: pharmacokinetics, pharmacodynamics, comorbidity burdens, and competing risks all change with age. When a trial enrolls neonates, children, adults, and older adults—or even…

Age-Specific Protocol Design, Pediatric and Geriatric Clinical Trials

Documenting Amendment Rationale for Submissions

August 10, 2025

digi

Documenting Amendment Rationale for Submissions How to Document the Rationale for Protocol Amendments in Submissions Why Amendment Rationale Is Critical Every protocol amendment submitted to a regulatory body or ethics committee must include a clearly documented rationale. This rationale helps authorities understand the context and justification for changes, evaluate risks and benefits, and determine whether…

Protocol Amendments and Version Control, Regulatory Submissions of Amendments

Overview of Centralized Monitoring in Risk-Based Monitoring (RBM)

August 10, 2025

digi

Overview of Centralized Monitoring in Risk-Based Monitoring (RBM) Understanding Centralized Monitoring in Risk-Based Monitoring What Is Centralized Monitoring in RBM? Centralized monitoring is a core component of Risk-Based Monitoring (RBM), enabling sponsors and CROs to detect data anomalies and site performance issues without on-site visits. Defined by ICH E6(R2), centralized monitoring involves the remote evaluation…

Centralized Monitoring Technique, Risk-Based Monitoring (RBM)

Core Responsibilities of a Regulatory Affairs Associate

August 10, 2025

digi

Core Responsibilities of a Regulatory Affairs Associate What Does a Regulatory Affairs Associate Do in Clinical Trials? 1. Introduction: The Regulatory Link Between Science and Compliance Regulatory Affairs Associates (RAAs) play a critical role in the clinical research ecosystem, ensuring that drug development activities meet all necessary legal and regulatory requirements. They act as the…

Career in Clinical Research, Regulatory Affairs Careers

Regulatory Guidance on Adaptive Methods in Rare Disease Trials

August 10, 2025

digi

Regulatory Guidance on Adaptive Methods in Rare Disease Trials Navigating Regulatory Guidance on Adaptive Designs in Rare Disease Trials Introduction: Regulatory Confidence in Adaptive Methods Adaptive designs offer a lifeline for efficient clinical development in rare diseases, where patient populations are small and traditional trial models are often unfeasible. However, this flexibility must operate within…

Adaptive Trial Designs, Rare and Orphan Disease Trials

Validation of Calibration Curves and QC Samples in Bioanalytical Methods for BA/BE

August 10, 2025

digi

Validation of Calibration Curves and QC Samples in Bioanalytical Methods for BA/BE How to Validate Calibration Curves and QC Samples in Bioanalytical Methodology for BE Studies Introduction: The Cornerstone of Reliable BA/BE Data In bioavailability and bioequivalence (BA/BE) studies, accurate and reproducible measurement of drug concentrations in biological matrices—usually plasma—is paramount. These measurements are based…

Analytical Method Validation, Bioavailability and Bioequivalence Studies (BA/BE)

Real-Time Tracking Technologies for Cold Chain

August 10, 2025

digi

Real-Time Tracking Technologies for Cold Chain Real-Time Tracking Technologies for an Inspection-Ready Vaccine Cold Chain Why Real-Time Tracking Matters: From Potency Protection to Defensible Evidence Cold chain integrity is the bridge between manufacturing quality and credible clinical outcomes. Traditional “download-on-arrival” data loggers are valuable, but they can’t prevent losses in transit or flag a warming…

Cold Chain Requirements, Vaccine Clinical Trials